Clinical studies
Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women

https://doi.org/10.1016/S0002-9343(99)80345-3Get rights and content

objective

To assess the benefit of cyclical etidronate plus ergocalciferol for the prevention of glucocorticoid-induced bone loss in a 2-year, prospective, open study based in an osteoporosis clinic.

Patients and methods

Group 1 consisted of 15 postmenopausal women (mean age 62.6 ± 3.3 years) who commenced glucocorticoid therapy and were treated with cyclical etidronate (400 mg/d for the first month; thereafter, 400 mg/d for 2 weeks of every 3-month period), elemental calcium (1 g/d), and ergocalciferol (0.5 mg/wk). Group 2 consisted of 11 postmenopausal women (mean age 60.2 ± 4.7 years) with glucocorticoidinduced osteoporosis, who were attending the clinic at the same time and were treated with calcium supplements only (1 g/d).

measurements

Lumbar spine and femoral neck bone mineral densities (BMD) were measured at baseline and after 12 and 24 months of glucocorticoid therapy using a dual energy x-ray absorptiometer.

Results

The two groups did not differ with respect to age, years since the menopause, mean daily glucocorticoid dose, and baseline BMD values. During the first year of therapy, mean lumbar spine BMD increased from an initial value of 0.88 g/cm2 to 0.94 g/cm2, an increase of 7% per year (95% confidence interval [CI]3.7% to 10.2%; P <0.001 compared with controls). Significant increases in BMD of 2.5% per year were also observed in the femoral neck (95% CI −1% to 6%; P <0.01 compared with controls). After the second year of cyclical etidronate therapy, femoral neck BMD continued to increase (P <0.05 compared with value at 12 months), while lumbar spine BMD remained stable.

Conclusion

Chronic glucocorticoid therapy may result in bone loss at most skeletal sites. Therapy with cyclical etidronate plus ergocalciferol not only prevented glucocorticoid-induced bone loss, but even increased lumbar spine and femoral neck BMD in postmenopausal women commencing glucocorticoid therapy.

References (32)

  • DempsterDW et al.

    Mean wall thickness and formation periods of trabecular bone packets in coticosteroid-induced osteoporosis

    Calcif Tissue Int.

    (1983)
  • DempsterDW

    Bone histomorphornetry in glucocorticoid-induced osteoporosis

    J Bone Miner Res.

    (1989)
  • ReidIR

    Pathogenesis and treatment of steroid osteoporosis

    Clin Endocrinol.

    (1989)
  • LukertBP et al.

    Glucocorticoid-induced osteoporosis: pathogenesis and management

    Ann Intern Med.

    (1990)
  • AvioliLV

    Effects of chronic corticosteroid therapy on mineral metabolism and calcium absorption

    Adv Exp Med Biol.

    (1984)
  • RaiszLG et al.

    Effect of glucocorticoids on bone resorption in tissue culture

    Endocrinology

    (1972)
  • Cited by (97)

    • Glucocorticoid-induced osteoporosis and Cushing’s syndrome

      2020, Marcus and Feldman’s Osteoporosis
    • Glucocorticoid-Induced Osteoporosis

      2013, Osteoporosis: Fourth Edition
    • Glucocorticoid-Induced Osteoporosis

      2008, Osteoporosis, Two-Volume Set
    • Ergocalciferol

      2007, xPharm: The Comprehensive Pharmacology Reference
    • Glucocorticoid-induced osteoporosis

      2003, Endocrinology and Metabolism Clinics of North America
    View all citing articles on Scopus
    View full text